Select your Country or Region

  • TargetMol | Compound LibraryArgentinaArgentina
  • TargetMol | Compound LibraryAustraliaAustralia
  • TargetMol | Compound LibraryAustriaAustria
  • TargetMol | Compound LibraryBelgiumBelgium
  • TargetMol | Compound LibraryBrazilBrazil
  • TargetMol | Compound LibraryBulgariaBulgaria
  • TargetMol | Compound LibraryCroatiaCroatia
  • TargetMol | Compound LibraryCyprusCyprus
  • TargetMol | Compound LibraryCzechCzech
  • TargetMol | Compound LibraryDenmarkDenmark
  • TargetMol | Compound LibraryEgyptEgypt
  • TargetMol | Compound LibraryEstoniaEstonia
  • TargetMol | Compound LibraryFinlandFinland
  • TargetMol | Compound LibraryFranceFrance
  • TargetMol | Compound LibraryGermanyGermany
  • TargetMol | Compound LibraryGreeceGreece
  • TargetMol | Compound LibraryHong KongHong Kong
  • TargetMol | Compound LibraryHungaryHungary
  • TargetMol | Compound LibraryIcelandIceland
  • TargetMol | Compound LibraryIndiaIndia
  • TargetMol | Compound LibraryIrelandIreland
  • TargetMol | Compound LibraryIsraelIsrael
  • TargetMol | Compound LibraryItalyItaly
  • TargetMol | Compound LibraryKoreaKorea
  • TargetMol | Compound LibraryLatviaLatvia
  • TargetMol | Compound LibraryLebanonLebanon
  • TargetMol | Compound LibraryMalaysiaMalaysia
  • TargetMol | Compound LibraryMaltaMalta
  • TargetMol | Compound LibraryMoroccoMorocco
  • TargetMol | Compound LibraryNetherlandsNetherlands
  • TargetMol | Compound LibraryNew ZealandNew Zealand
  • TargetMol | Compound LibraryNorwayNorway
  • TargetMol | Compound LibraryPolandPoland
  • TargetMol | Compound LibraryPortugalPortugal
  • TargetMol | Compound LibraryRomaniaRomania
  • TargetMol | Compound LibrarySingaporeSingapore
  • TargetMol | Compound LibrarySlovakiaSlovakia
  • TargetMol | Compound LibrarySloveniaSlovenia
  • TargetMol | Compound LibrarySpainSpain
  • TargetMol | Compound LibrarySwedenSweden
  • TargetMol | Compound LibrarySwitzerlandSwitzerland
  • TargetMol | Compound LibraryTaiwan,ChinaTaiwan,China
  • TargetMol | Compound LibraryThailandThailand
  • TargetMol | Compound LibraryTurkeyTurkey
  • TargetMol | Compound LibraryUnited KingdomUnited Kingdom
  • TargetMol | Compound LibraryUnited StatesUnited States
  • TargetMol | Compound LibraryOther CountriesOther Countries
Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

Sodium Oxamate

Sodium Oxamate
Contact us for more batch information
Select Batch
Resource Download

Sodium Oxamate

Catalog No. T19831Cas No. 565-73-1
Sodium Oxamate (Oxamic acid sodium salt) is an LDH inhibitor that specifically inhibits LDHA. Sodium Oxamate has antitumor activity and induces cell cycle arrest and apoptosis.
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Pack SizePriceAvailabilityQuantity
1 g$31In Stock
1 mL x 10 mM (in H2O)$39In Stock
Bulk & Custom
Add to Cart
Questions
View More

Related Compound Libraries of "Sodium Oxamate"

Product Introduction

Bioactivity
Description
Sodium Oxamate (Oxamic acid sodium salt) is an LDH inhibitor that specifically inhibits LDHA. Sodium Oxamate has antitumor activity and induces cell cycle arrest and apoptosis.
In vitro
METHODS: Human lung cancer cells H1299, A549 and normal human bronchial epithelial cells HBE were treated with Sodium Oxamate (1-100 mmol/L) for 24 h. Cell viability was measured by CCK-8 assay.
RESULTS: Sodium Oxamate significantly inhibited the cell viability of H1299 and A549 cells in a dose-dependent manner, with IC50 of 32.13±2.50 and 19.67±1.53 mmol/L, respectively. Sodium Oxamate had almost no effect on HBE cells, with an IC50 of 96.73±7.60 mmol/L. [1].
METHODS: Human lung cancer cells A549 and normal human bronchial epithelial cells HBE were treated with Sodium Oxamate (20-100 mmol/L) for 24 h, and several intracellular biochemical parameters were measured.
RESULTS: LDH activity, ATP content and NADPH/NADP ratio were significantly decreased and ROS content was significantly increased in A549 cells after Sodium Oxamate treatment. In contrast, glucose metabolism was less affected, although LDH enzyme was also inhibited in a dose-dependent manner in HBE cells. [2]
In vivo
METHODS: To detect the antitumor activity in vivo, Sodium Oxamate (300 mg/kg once a day) and pembrolizumab (10 mg/kg twice a week) were intraperitoneally injected into B-NDG mice carrying human lung cancer tumor H1299 for fifteen days.
RESULTS: Both Sodium Oxamate and pembrolizumab significantly delayed tumor growth in monotherapy, and the combination therapy was more effective. [1]
METHODS: To explore the potential for the treatment of diabetes, Sodium Oxamate (350-750 mg/kg) was administered intraperitoneally to db/db mice once daily for twelve weeks.
RESULTS: Sodium Oxamate treatment reduced body weight gain, blood glucose and HbA1c levels, and improved insulin secretion, pancreatic islet morphology, and insulin sensitivity in db/db mice.Sodium Oxamate improves glycemic control and insulin sensitivity in db/db mice, primarily by inhibiting the production of tissue lactic acid. [3]
Aliasoxamate sodium, Oxamic acid sodium salt, Aminooxoacetic acid sodium salt, SO
Chemical Properties
Molecular Weight111.03
FormulaC2H2NNaO3
Cas No.565-73-1
Storage & Solubility Information
Storage Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Solubility Information
H2O: 16.67mg/ml(150mM)
DMSO: Insoluble
Solution Preparation Table
H2O
1mg5mg10mg50mg
1 mM9.0066 mL45.0329 mL90.0657 mL450.3287 mL
5 mM1.8013 mL9.0066 mL18.0131 mL90.0657 mL
10 mM0.9007 mL4.5033 mL9.0066 mL45.0329 mL
20 mM0.4503 mL2.2516 mL4.5033 mL22.5164 mL
50 mM0.1801 mL0.9007 mL1.8013 mL9.0066 mL
100 mM0.0901 mL0.4503 mL0.9007 mL4.5033 mL

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
TargetMol | Animal experimentsFor example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . TargetMol | Animal experiments A total of 10 animals were administered, and the formula you used is 5% TargetMol | reagent DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。
Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSOTargetMol | reagent (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
Preparation method for in vivo formula: Take 50 μL DMSOTargetMol | reagent main solution, add 300 μLPEG300TargetMol | reagent mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2OTargetMol | reagent mix well and clarify
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
%Tween 80
%ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords